Efineptakin alfa

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameEfineptakin alfa
Drug Alias Name依非白介素αIL-7-hyFcHyLeukinInterleukin-7-hybrid-Fc-recombinant-proteinHyLeukin-7 +[11] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-2 receptor modulatorsInterleukin-7 receptor subunit alpha agonists
TargetsInterleukin-7 receptor subunit alphaInterleukin-2 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursLymphopenia +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandSouth Korea +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesI-Mab Biopharma Us LtdGannex Pharma Co LtdNational Institutes Of Health +[12] 
Inactive CompaniesPt Kalbe Genexine BiologicsNational Cancer Institute
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursLymphopenia +[19] 
Inactive IndicationsUrinary Bladder NeoplasmsOropharyngeal NeoplasmsHypopharyngeal Neoplasms +[13] 

Other Information

ATC CodeN/A
Related LinksN/A